Vnitr Lek 2014, 60(11):942-947

New aspects of hormone replacement therapy

Tomáš Fait
Gynekologicko-porodnická klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Alois Martan, DrSc.

All existing recommendations sign hormone replacement therapy (HRT) as first therapy for acute climacteric syndrome. The low dose vaginal therapy is the first choice for prevention and therapy of urogenital atrophy and its complications. Early start of HRT has neutral or slightly beneficial influence on ischaemic heart disease. It is sure that HRT is effective in prevention and therapy of postmenopausal osteoporosis. Long term therapy must be individualized on base of benefits to risks ratio with differences by type of HRT.

Keywords: acute climacteric syndrome; hormone replacement therapy; ischaemic heart disease; osteoporosis; urogenital atrophy

Received: September 5, 2014; Accepted: October 2, 2014; Published: November 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fait T. New aspects of hormone replacement therapy. Vnitr Lek. 2014;60(11):942-947.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Fait T, Donát J, Jeniček J et al. Doporučení pro hormonální substituční terapii v postmenopauze. Čes Gynek 2010; 75(2): 109-110.
    2. Birkhauser MH, Panay N, Archer DF et al. Updated recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2008; 11(2): 108-123. Go to original source... Go to PubMed...
    3. Utian WH, Archer DF, Bachmann GA. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008; 15(4 Pt 1): 584-602. Go to PubMed...
    4. Archer DF, Baber RJ, Barlow D et al. Updated IMS recommendations on postmenopusal hormone therapy and preventive strategie for midlife health. Climacteric 2011; 14(3): 302-320. Go to original source... Go to PubMed...
    5. Sannten RJ, Allred DC, Ardoin SP et al. Postmenopausal Hormone Therapy. An Edocrine Society Scientific Statement. J Clin Endocrinol Metabol 2010; 95(7 Suppl 1): S1-S66. Go to original source... Go to PubMed...
    6. Nelson HD, Walker M, Zakher B et al. Menopausal hormone therapy for the primary prevention of chronic medication: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med 2012; 157(2): 104-113. Go to original source... Go to PubMed...
    7. Marjoribanks J, Farquhar C, Roberts H et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012; 7: CD004143. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD004143.pub4>. Go to original source... Go to PubMed...
    8. Colditz GA, Willett WC, Stampfer MJ et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316(18): 1105-1110. Go to original source... Go to PubMed...
    9. Busch TL, Barrett-Connor E, Cowan LD et al. Cardiovascular mortality and noncontraceptive use of estrogen in women. Circulation 1987; 75(6): 1102-1109. Go to original source... Go to PubMed...
    10. Sullivan JM, Vander Zwaag R, Hughes JP et al. Estrogen replacement and coronary artery disease. Arch Intern Med 1990; 150(12): 2557-2562. Go to original source...
    11. Sullivan JM, Vander Zwaag R, Lemp GF et al. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988; 108(3): 358-363. Go to original source... Go to PubMed...
    12. Gruchow HW, Anderson AJ, Barboriah JJ et al. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988; 115(5): 954-963. Go to original source... Go to PubMed...
    13. Grodstein F, Manson JE, Colditz GA et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133(12): 933-941. Go to original source... Go to PubMed...
    14. Hulley S, Grady D, Bush T et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280(7): 605-613. Go to original source... Go to PubMed...
    15. Clarke S, Kelleher J, Lloyd-Jones H et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002; 109(9): 1056-1062. Go to original source... Go to PubMed...
    16. Angerer P, Stork S, Kothny W et al. Effect of postmenopausal hormone replacement on atherosclerosis in femoral arteries. Maturitas 2002; 41(1): 51-60. Go to original source... Go to PubMed...
    17. Waters P, Alderman EL, Hsia J et al. Effects of HRT and antioxidant vitamin supplememts on coronary atherosclerosis in postmenopausal women. JAMA 2002; 288(19): 3433-3440. Go to original source... Go to PubMed...
    18. Hodis HN, Mack WJ. Atheroslerosis Imaging methods: Assessing cardiovascular disease and evaluating the role of estrogen in prevention of atherosclerosis. Am J Cardiol 2002; 89(12A): 19E-27E; discussion 27E. Go to original source... Go to PubMed...
    19. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321-333. Go to original source... Go to PubMed...
    20. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291(14): 1701-1712. Go to original source... Go to PubMed...
    21. Salpeter SR, Walsh JME, Greyber E et al. Mortality associated with HRT in younger and older women. J Gen Intern Med 2004; 19(7): 791-804. Go to original source... Go to PubMed...
    22. Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297(13): 1465-1477. Go to original source... Go to PubMed...
    23. Allison MA, Manson JE, Langer RD et al. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. Menopause 2008; 15(4 Pt 1): 639-647. Go to original source... Go to PubMed...
    24. Collins P, Rosano G, Casey C et al. Management of cardiovascular risk in peri-menopausal woman. Eur Heart J 2007; 28(16): 2028-2040. Go to original source... Go to PubMed...
    25. Manson JE. The Kronos Early Estrogen Prevention Study by Charlotte Barker. Womens Health (Lond Engl) 2013; 9(1): 9-11. Go to original source... Go to PubMed...
    26. Schierbeck LL, Rejnmark L, Tofteng CL et al. Efect of HRT on cardiovascular events in recently postmenopausal women. BMJ 2012; 345: e6409. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.e6409>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.